Based on the preservation of the IκBα-NFκB complex via proteasome inhibition and the subsequent blockade of NFκB-mediated inflammation, proteasome inhibitors have emerged as potential therapies for treating several inflammatory conditions, including adjuvant-induced arthritis [43], acute pancreatitis [44], hypercholesterolemia-associated renal disease [45], and endotoxemia lethality [46], [47]. The gene discussed is NFKB1; the disease is serum lipopolysaccharide activity.